KELOWNA, BC / ACCESSWIRE / November 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DEM-A22-1 is expected to begin on November 15, 2022. This is Lexaria's first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol ("CBD")… Read More..

PRINCETON, N.J., Nov. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2022. "We… Read More..

Launch of Centers of Excellence Strategy Increases Outlook for Growth BOSTON, November 09, 2022--(BUSINESS WIRE)--Bionik Laboratories Corp. (OTCPINK: BNKL), a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges, today reported financial results for the second quarter of fiscal year 2023, ended… Read More..